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We have previously shown that topoisomerase I (topo I) antagonist inhibited retrovirus replication. Since tyrphostins, synthetic compounds and 
protein tyrosine kinases (PTKs) blockers, inhibited topo I activity (manuscript in preparation) we examined their ability to inhibit Moloney murine 
leukemia virus (MO-MuLV) replication. We found that non-cytotoxic doses of tyrphostin derivatives (AG-555, AG-18) blocked or substantially 
reduced MO-MuLV replication in acute or chronically infected NIH13T3 cells. Our experiments uggest hat the antiviral effect of these tyrphostin 
derivatives was not the result of antiproliferative activity. However, the tyrphostin derivatives used in our present investigation differ in their ability 
to inhibit MO-MuLV replication. Furthermore, as expected from stereospecific competitive inhibitors, the antiviral effect is not a general characteristic 
of all tyrphostin derivatives, since AG-213 does not affect MO-MuLV replication. Our results indicate that these tyrphostin derivatives may represent 
a novel class of antiretroviral drugs. 
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1. Introduction 
Retroviruses have been etiologically implicated with 
leukemia in humans and animals. Human T-cell leuke- 
mia virus type 1 (HTLV-I) causes adult T-cell leukemia 
(ATL), particularly in high endemic areas of the virus 
such as Japan and the Caribbean [l] and human T-cell 
leukemia virus type 2 (HTLV-II) is involved in hairy cell 
leukemia [2]. Murine leukemia viruses, such as Moloney 
murine leukemia virus (MO-MuLV), are classical replica- 
tion competent retroviruses that lack oncogenes. They 
induce leukemias or other hematopoeitic neoplasm with 
long latency, and MO-MuLV induced T-cell leukemia, 
characterized by an enlargement of the spleen and/or the 
thymus [3]. The clinical importance of retroviruses as the 
causative agent of severe diseases in humans and ani- 
mals, has led to intensive research aimed at developing 
specific antiretroviral drugs. One basis for the develop- 
ment of new drugs is an increased understanding of the 
virus life cycle and the enzymes involved in its replica- 
tion. We showed that topoisomerase-I (topo-I) activity 
is associated with retroviral particles (Human immu- 
nodeficiency virus (HIV), equine infectious anemia virus 
(EIAV) and MO-MuLV) and is inhibited by camptothe- 
tin (CPT), a specific inhibitor of eukaryotic topo-I [4]. 
We have also demonstrated that non-cytotoxic doses of 
CPT inhibited retroviral replication (HIV, EIAV) in 
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acute and chronically infected cells [5,6], and that CPT 
blocked and prevented retroviral-induced diseases in 
mice [7]. 
Topoisomerases are essential enzymes which control 
and modify the topological state of DNA and are the 
main targets for anticancer drugs [8-lo]. Topo-I cata- 
lyzes the concerted breakage and rejoining of a single 
strand of the DNA helix, and passes another strand 
through the transient break before resealing. 
The breakage step is characterized by a covalent bond 
formed between the tyrosine residue (present in the en- 
zyme active site) and the phosphate moiety of the DNA 
backbone. Since this activity resembles tyrosine phos- 
phorylation, we assumed that inhibitors of tyrosine ki- 
nases may suppress topo-I activity. It was found that 
genistein, which blocks the epidermal growth factor 
(EGF) receptor kinase, also inhibited topo II activity 
[l 11. Our preliminary results indicate that tyrphostins - 
tyrosine kinase antagonists, inhibit topo-I activity (man- 
uscript in preparation). 
Tyrphostins are synthetic compounds which inhibit 
tyrosine kinases, i.e. EGF [12,13], PDGF receptors 
[14,15] and the erb-B2/neu kinase [16]. Certain tyr- 
phostins block cell proliferation and their cytotoxicity in 
tissue culture cells (normal keratinocytes, lymphocytes) 
is very low and occurs at concentrations above 200 PM 
[13,16-181. 
Since we showed that topo-I inhibitors can act as an- 
tiretroviral drugs and that tyrphostin derivatives inhibit 
eukaryotic topo-I activity in vitro (manuscript in prepa- 
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ration), we examined the effect of tyrphostins on Mo- 
MuLV replication, and found that non-cytotoxic doses 
of two tyrphostin derivatives (AG-555 and AG-I8), in- 
hibited MO-MuLV replication in acute and in chroni- 
cally infected NIH13T3 cells. 
2. Materials and metlwds 
2.1. Cells and viruses 
Cells: NIH13T3 and NIH/3T3/Mo-MuLV cell lines were grown in 
Dulbecco’s modified Eagle medium supplemented with 10% fetal calf 
serum, 1% penicillin-streptomycin and 1% L-glutamine. 
MO-MuiP? The culture supdrnatant of NIki/3T3/Mo-MuLV chroni- 
cally infected cells (106/ml) was collected and centrifuged (3000 t-pm, 10 
min) from cell debris. 1 ml of this supernatant contained 3 x lo6 plaque 
forming units (PFU). 
2.2. Compounds 
Tyrophostin derivatives: AG-555, AG-18 and AG-213 were received 
from Dr. A. Levitzki, Hebrew University, Jerusalem. Stock solutions 
of the drugs, 10 mM or 100 mM in 100% dimethyl sulfoxide (DMSO), 
were stored at -20°C and diluted with culture medium before being 
added to the cells. The final concentration of DMSO in the culture 
medium was less than 1.5%. 
2.3. MO-MuLV acute infection of NIHl3T3 cells and tyrphostin 
treatment 
Culture supernatant (0.1 ml) containing 3 x 10’ PFU of MO-MuLV 
was used for infecting lo5 NIH73T3 cells treated with polybrene (8 
&ml) in the presence or absence of different concentrations of AG- 
555, AC-18 or AG-213, and control cells received equivalent volumes 
of DMSO. Cells were incubated for 1 h at 37”C, washed and resus- 
pended in fresh media in the presence or absence of tyrphostins (SO-150 
PM) for 20 h at 37°C. 
Reverse transcriptase (RT) activity in the culture media was meas- 
ured 7 days after infection as described [191, and the ICsO (50% inhibit- 
ing concentration) for each tyrphostin was determined. 
2.4. Tyrphost~n treatm~t of chronically infected cells 
NIH/3T3/Mo-MuLV chronically infected cells (lO?flask) were 
treated with 50-150 uM AG-555 or AG-18 for 20 hat 37°C. RT activitv 
was measured in the culture medium 48 h following treatment. For 
long-term tyrphostin treatment, lo6 NIH/3T3IMo-MuLV cells were 
treated with 0.510 PM AG-555 or AG-18. Fresh medium containing 
tyrphostins was added every 4 days, and cells were diluted to lo6 cells 
per plate. RT activity was measured in MO-MuLV particles isolated 
from the culture medium 13 days after the first tyrphostin treatment. 
Cell viability was determined by the trypan blue exclusion assay and 
cell growth by cell counting. 
2.4. Qrphostin cytotoxicity 
To determine the cvtotoxic effect of tvrnhostin derivatives (AG-555. 
AG-18 or AC-213): NIH13T3 uninfected cells and NIHj3T3/Mo- 
MuLV chronically infected cells were cultivated at lo5 cells/well in 
24-well Costar dishes. Following over-night incubation, fresh media 
containing increasing drug concentrations were added for 20 h. Equiv- 
alent volumes of DMSO were administered to untreated control cells. 
Following incubation all cells were washed and resuspended in fresh 
medium. 
Cell viability was measured by ‘Neutral red assay’ [20] 48 h after 
tyrphostin treatment, and the CC% value (cytotoxicity concentration 
50%) for each drug was determined. 
2.6. Immunoblot analysis 
Viral particles from the different reatments were obtained by precip- 
itation of the virus from the culture media as described [5]. The virus 
pellet was resuspended in a 50 ~1 RIPA buffer (50 mM Tris-HCl, pH 
7.5,0.5 M NaHPO,, 0.5% NP-40,0.25% Na-deoxycholate, 0.1% SDS). 
Equal volumes of viral lysate were analyzed on a 5-20% gradient 
SDS-PAGE, and Western blot analysis was performed using 1: 1500 
dilution of MO-MuLV pl5 antibodies. The blot was developed by using 
the Western blotting detection reagents; enhanced chemiluminescence 
(ECL) (Amersham). 
3. Results 
3.1. Tyrphostin derivatives (AG-555, AG-18 and 
AG-213) inhibit MO-MuLV replication in acute 
infection of ~~~l3T3 cells 
To determine the appropriate concentrations of 
AG-55.5, AG-18 and AG-213 which permit viability and 
growth of NIH/3T3 cells, and NIH/3T3/MoMuLV 
infected cells, we treated these cells with different doses 
of the tyrphostin derivatives, and measured cell viability 
and growth by the Neutral Red Assay [ZO]. CCSO of all 
three derivatives was observed at concentrations above 
200 PM for both cell types (Table 1). 
To examine the effect of tyrphostins on MO-MuLV 
replication, NIH/3T3 cells were infected with MO-MuLV 
(as described in section 2) in the absence or presence of 
non-cytotoxic doses of tyrphostin derivatives. The cells 
were treated with different doses of tyrphostins for 20 h, 
washed and fresh medium was added. Reverse transcrip- 
tase activity in the culture media was measured 7 days 
after infection. Two of the tyrphostin derivatives ignifi- 
cantly inhibited MO-MuLV replication at concentrations 
6- to 20-fold lower than the doses required for cytotoxic 
effect. As can be seen from Table 1, the IC,, for AG-55 
and AG-18 was 10 ,uM and 40 PM while the CC,, was 
210 ,uM and 250 ,uM, respectively. 
It should be noted that the doses of AG-555 which 
inhibited MO-MuLV replication were four times lower 
than the inhibitory doses of AG-18. Interestingly, AG- 
213, another tyrphostin derivative, did not affect Mo- 
MuLV replication (Table 1). 
The reduction in MO-MuLV production following tyr- 
phostin treatment was confirmed by analyzing the pres- 
ence of virus antigen in the culture media. Virus particles 
were pelleted, lysed and their proteins were separated by 
electrophoresis and assayed by Western blot analysis 
using MO-MuLV p15 antibodies. ~15 was present in the 
Table 1 
Comparative ffect of tyrphostin derivatives on MO-MuLV replication 
and cell growth 
RT inhibition Cell growth inhibition 
Compounds IC, t&M) 
$) NIH/3T3 
NIH13T31 
MO-MuLV 
AG-555 10.8 + 2.1 210 + 25.4 210 f 29.1 
AG-18 40 + 10.3 250 f 23.8 240 f 14.7 
AG-213 No effect 230 + 18.5 235 f 31.4 
RT inhibition was measured in acute infection of NIH13T3 cells by 
MO-MuLV and cell viability was determined using the ‘Neutral red 
assay’ as detailed in section 2. All data are mean + SD. from 3 exper- 
iments. 
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Fig. 1. Effect of tyrphostin AG-555 on MO-MuLV p15 expression 
detected by immunoblot analysis. NIW3T3 cells (lo5 per dish) were 
infected with MO-MuLV and treated with AG-555 (100pM and 10pM) 
for 20 h. The virus was pelleted from culture supematants 7days after 
infection. Viral lysate was prepared and the proteins were separated on 
polyacrylamide gel. Western blot analysis was performed using Mo- 
MuLV p-15 polyclonal antibodies, and the blot was developed using 
the ECL immuno-detection kit. The pellet from uninfected and un- 
treated cells (lane l), virus from untreated infected cells (lane 2), virus 
from infected cells treated only with 4% DMSO (lane 3) and virus from 
mfected cells treated with 100 PM and 10 ,uM AG-555 lanes 4 and 5, 
respectively. 
culture media 7 days after infection of NIH/3T3 cells 
with MO-MuLV (Fig. 1, lane 2) while the level of ~15 
was significantly decreased or absent following tyr- 
phostin AG-555 treatment (Fig. 1, lanes 4,5). These re- 
sults are compatible with the RT results and indicate that 
tyrphostins added during viral infection prevent subse- 
quent MO-MuLV replication. This also suggests that the 
inhibitory effect of AG-555 and AG-18 on MO-MuLV 
replication is due to their effect on the virus replication, 
and is not a result of their antiproliferative property. To 
examine the inhibitory efficacy of tyrphostins adminis- 
tered following virus infection, NIH/3T3 cells were in- 
fected with MO-MuLV and treated with different doses 
of tyrphostins one or three days post virus infection. As 
can be seen in Table 2, 81-86% inhibition of MO-MuLV 
replication was observed when 100 ,uM of tyrphostins 
were administered one or three days post virus infection. 
Lower concentrations of these drugs were less effective 
and at 50 ,uM, the efficacy of AG-555 was 4-fold higher 
than AG-18. 
3.2. The effect of AG-555 and AG-18 on MO-MuLV 
replication in NIHI3T3IMo-MuLV chronically 
infected cells 
Our results indicate that tyrphostin treatment inhibits 
MO-MuLV replication in acute infection of NIH/3T3 
cells. In order to evaluate their effect on chronically in- 
fected cells, NIH/3T3/Mo-MuLV cells were treated with 
50 PM or 150 ,uM of AG-555 or AG-18 for 20 h. Forty- 
eight hours later, RT activity was measured in the culture 
medium. As shown in Fig. 2, AG-555 at concentrations 
of 50 FM and 150 ,uM inhibited virus replication by 78% 
to 87%, while equal doses of AG-18 showed a reduction 
from 33% to 46%. These results indicate that AG-555 
significantly reduced MO-MuLV replication in chroni- 
cally infected cells and, in this respect, it is more effective 
than AG- 18. We also examined the influence of a long- 
term treatment of tyrphostins using very low doses of 
these drugs (0.5-10 PM). Chronically infected lo6 Mo- 
MuLV/NIH/3T3 cells were treated with tyrphostins, 
fresh medium containing these compounds was added 
every 4 days, and RT activity was measured 13 days after 
the first tyrphostin treatment. As shown in Fig. 3, 80- 
90% inhibition of MO-MuLV replication was observed 
13 days after continuous AG-555 treatment. During this 
period of tyrphostin treatment no effect on cell viability 
or cell growth was observed. The results also show that 
treatment with AG-555 was significantly more efficient 
than with AG-18. 
4. Discussion 
We have previously shown that the topo I specific 
antagonist inhibits retroviral replication in vitro [5,6] 
and prevents the onset of retroviral induced diseases in 
vivo [7]. In our present work, we demonstrated the abil- 
ity of tyrphostins, which are tyrosine kinases antago- 
nists, to inhibit MO-MuLV replication in acute and in 
chronically infected NIH/3T3 cells. This inhibitory effect 
is not due to possible cytotoxic effects of the tyrphostins, 
since non-cytotoxic doses of three different tyrphostin 
derivatives were used. Moreover, these compounds are 
Table 2 
Effect of tyrphostins administered after the infection process on Mo- 
MuLV replication in NIH13T3 cells 
1 Day post-inf. 3 Days post-inf. 
RT (cpm) 8 Inhibition RT (cpm) % Inhibition 
Control 19158 f 390 19158 f 390 
AG-555 4000+ 220 79 f 5 6064 f 178 68 + 7 
50 PM 
AG-555 2683f 53 86f3 3684f35 81 f9 
100jfM 
AG-18 8317 + 66 56 f 3 20446 f450 0 
50 PM 
AG-18 4149f113 78f6 8899 f 420 53 f 5 
100pM 
NIW3T3 cells (10’) were infected with MO-MuLV and treated with 50 
and 100 PM AG-555 or AG-18 for 20 h. The drugs were added to the 
culture media 1 or 3 days after virus infection. The data are 
mean f S.D. from 3 different experiments. 
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effective in inhibiting MO-MuLV replication even when 
administered three days post virus infection. In addition, 
we showed that these compounds also reduced Mo- 
MuLV replication in chronically infected NIH/3T3 cells. 
Although a short-term treatment (20 h) with 50 ,uM- 
150 ,uM was effective, a long-term treatment (13 days), 
using low doses of these drugs (0.5 PM-10 PM), showed 
a high efficacy in inhibiting MO-MuLV replication. 
Agents such as RT inhibitors [22] which block retrovi- 
ral replication, act at early stages of the viral infection 
process, while other agents, such as a-interferon, have 
been reported to suppress retroviral expression in chron- 
ically infected cells [23]. Tyrphostins appear to act as 
antiviral drugs at both levels and, under certain condi- 
tions, are capable of both blocking the initial stage of 
retroviral infection and reducing viral production in 
chronically infected cells thus, presenting potential ad- 
vantages over drugs that function only on one level. The 
mechanism by which these drugs act as antiviral inhib- 
itors is not clear. Since we found that tyrphostins inhib- 
ited topo-I activity in vitro (unpublished ata) and previ- 
ously demonstrated that topo-I specific inhibitors block 
retrovirus replication [5,6], it is possible that the influ- 
ence of these drugs on the virus replication is due to their 
effect on topo-I activity. However, it is also conceivable 
that tyrphostins act as antiviral drugs by influencing the 
activity of other viral proteins. The effect of tyrphostins 
on retrovirus replication may also be due to their impact 
on cellular proteins involved in the replication of retro- 
viruses (such as, cellular proteins required for efficient 
virus integration, cellular enzymes which are necessary 
for the transcription of the viral genome, etc.). It is feasi- 
ble that some tyrphostins have more than one mecha- 
nism of action and AG-555 and AG-18 may affect virus 
proteins and cellular proteins. For example, tyrphostin 
AG-213 which is an EGFR kinase blocker, has been 
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Fig. 2. Effect of tyrophostins on chronically infected NIH/3T3IMo- 
MuLV cells. NIH3T3/Mo-MuLV chronically infected cells (lo5 per 
dish) were treated with 50 PM and 150 PM AG-555 or AG-18 for 20 
h, and RT activity in the culture medium was measured 48 hrs post- 
treatment. The data are mean f S.D. from 3 different experiments. 
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Fig. 3. Long-term treatment of tyrphostin in chronically infected 
NIH3T3/Mo-MuLV cells. NIH/3T3IMo-MuLV chronically infected 
cells (lo6 per dish) were treated with low doses (0.5, 5, 10 ,uM) of 
AG-555 or AG-18. Fresh medium containing tyrphostins was added 
every 4 days, cells were diluted to lo6 cells per plate, and RT activity 
was measured 13 days after the first tyrphostin treatment. The data are 
mean + S.D. from 3 independent experiments. 
found to possess an antiproliferative ffect that may not 
be related to its EGFR kinase inhibitory activity [21]. 
Interestingly, we found that AG-555 is significantly 
more effective in inhibiting MO-MuLV replication than 
AG-18, and AG-213 does not have a significant effect. 
These differences in the retrovirus inhibition are not di- 
rectly correlated to their anti-tyrosine kinase activity. 
AG-555 and AG-213 are very potent protein tyrosine 
kinase inhibitors, whereas AG-18 exhibits a lower anti- 
PTK activity (A. Levitzki, personal communication). 
Since tyrphostins have an antiproliferative effect but 
are not toxic to cell growth and the addition of AG-2 13 
to acute infection of NIH/3T3 cells did not inhibit Mo- 
MuLV replication, we may therefore assume that the 
inhibitory effect of AG-555 and AG-18 is not solely due 
to their antiproliferative effect. 
Our results suggest hat tyrphostins may represent a 
new class of drug with an antiretroviral potential. The 
mechanism by which these agents act as antiviral inhib- 
itors and the stages in the virus life cycle which are 
influenced by these drugs are presently under investiga- 
tion. 
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